An entire endcap of nothing but hand sanitizer
When’s the last time an entire endcap has been dedicated against hand sanitizer?
That’s the power of the novel H1N1 pandemic flu that will be returning to a school/workplace near you this fall. What are the chances this endcap will be rampant with empty spaces after the first few months of the season?
Probably not pretty good, but only because CVS will likely fill that space with something else. Even with a heightened retail focus around sanitizers this year, the demand on hand sanitizers may just be that great.
Report: Primary care physicians decreasing, giving way to retail clinic use
NEW YORK The shortage of primary care physicians is bound to escalate as long hours, lower pay, less prestige and more administrative headaches are turning doctors instead toward more lucrative subspecialties, according to a recent USA Today report.
With primary care losing its pull, retail-based health clinics will play an increasingly important role in the frontline for wellness and preventative-care programs.
The number of U.S. medical school students going into primary care has plummeted 51.8% since 1997, USA Today reported, citing data from the American Academy of Family Physicians. The AAFP, which represents more than 93,000 physicians, predicts a shortage of 40,000 family physicians in 2020, when demand is expected to spike.
The report also states that the U.S. healthcare system has roughly 100,000 family physicians and will need nearly 140,000 in 10 years. At the core of the demand: The 78 million Baby Boomers who begin to turn 65 in 2011 and will require increasing medical care.
Furthermore, the need for more doctors will rise if Congress passes healthcare legislation that extends insurance coverage to a significant portion of the 47 million Americans who lack insurance, USA Today reported.
Finding a physician will become more difficult, waits for appointments will grow longer and more people will turn to emergency rooms, which are already overflowing, Ted Epperly, president of the AAFP, told USA Today.
Teva launches ‘Patient First’ project
NEW YORK Most consumers may not know a lot about biosimilar equivalence, immunogenicity or what “monoclonal antibody” means, but they know that battling a chronic disease can be a frightening and financially devastating prospect. Teva’s new TV campaign is a very sobering reminder of what many already know at a time when all of America is focused on fixing health care.
On one end of the continuum of prescription drug prices lies generic drugs purchased under one of the growing number of generic discount programs offered by retailers for less than $50 a year. On the other end lies biotech drugs that can cost nearly half a million dollars a year.
This is a reminder to politicians and voters that for many patients, manageable diseases carry unmanageable costs. This especially is true for such diseases as cancer, multiple sclerosis and paroxysmal nocturnal hemoglobinuria. Rob Day, one of the patients profiled in the “Patient First” campaign — itself a part of the broader Year of Affordable Healthcare campaign — was diagnosed with PNH at age 19 and must pay $389,000 a year for biotech drugs to treat it.
While $389,000 is an extreme example, most biotech drugs remain incredibly expensive: A year’s supply of Genentech’s breast cancer drug Herceptin (trastuzumab) costs about $40,000, while a single vial of Elan Corp.’s multiple sclerosis drug Tysabri (natalizumab) costs more than $2,000. Setting up a regulatory environment that allows expensive biotech drugs to face competition from biosimilars would help to alleviate the fears and financial strain of some patients living with chronic illnesses.